Elanco In-feed BRD Therapy Drug Approved By FDA
The U.S. Food and Drug Administration approved Elanco’s new in-feed antimicrobial, Pulmotil (tilmicosin), for treatment of Bovine Respiratory Disease in groups of cattle in the early stages of a BRD outbreak, the company reported today.
The FDA approved Pulmotil for the control of BRD associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni in groups of beef and non-lactating dairy cattle, where active BRD has been diagnosed in at least 10 percent of the animals in the group. It can be fed to cattle within the first 45 days after arrival. Elanco said the in-feed therapy, which lasts 14 days, reduces stress associated with cattle handling.
The FDA requires a veterinarian to issue a Veterinary Feed Directive (VFD) for the use of Pulmotil. Elanco said it will help facilitate the VFD process through training and ongoing support.
Before making the product widely available, Elanco said it will conduct additional commercial trials and work with veterinarians and their clients to develop protocols that support the VFD process and maximize Pulmotil’s value in a variety of commercial settings.
Elanco, based in Greenfield, Ind., is a division of Eli Lilly and Co.